Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest
Rev Esp Cardiol (Engl Ed). 2020 Nov;73(11):893-901.
doi: 10.1016/j.rec.2020.01.005.
Epub 2020 Mar 6.
[Article in
English,
Spanish]
Authors
Giuseppe Gargiulo
1
, Marco Valgimigli
2
, Mikael Sunnåker
3
, Pascal Vranckx
4
, Enrico Frigoli
5
, Sergio Leonardi
6
, Alessandro Spirito
5
, Felice Gragnano
7
, Negar Manavifar
5
, Roberto Galea
5
, Alberto R De Caterina
8
, Paolo Calabrò
9
, Giovanni Esposito
10
, Stephan Windecker
5
, Lukas Hunziker
5
Affiliations
- 1 Department of Cardiology, Bern University Hospital, Bern, Switzerland; Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
- 2 Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address: marco.valgimigli@insel.ch.
- 3 Clinical Trials Unit (CTU) Bern, University of Bern, Bern, Switzerland.
- 4 Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium & Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
- 5 Department of Cardiology, Bern University Hospital, Bern, Switzerland.
- 6 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 7 Department of Cardiology, Bern University Hospital, Bern, Switzerland; Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 8 Ospedale del Cuore - Massa, Fondazione Toscana "G. Monasterio", Pisa, Italy.
- 9 Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- 10 Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
Abstract
Introduction and objectives:
Patients who are vulnerable to hemodynamic or electrical disorders (VP) are often excluded from clinical trials and data on the optimal access-site or antithrombotic treatment are limited. We assessed outcomes of transradial vs transfemoral access and bivalirudin vs unfractionated heparin (UFH) in VP with acute coronary syndrome undergoing invasive management.
Methods:
The MATRIX trial randomized 8404 patients to radial or femoral access and 7213 patients to bivalirudin or UFH. Among them, 934 (11.1%) were deemed VP due to advanced Killip class (n = 808), cardiac arrest (n = 168), or both (n = 42). The 30-day coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE: death, myocardial infarction, or stroke) and net adverse clinical events (NACE: MACE or major bleeding).
Results:
MACE and NACE were similarly reduced with radial vs femoral access in VP and non-VP. Transradial access was also associated with consistent relative benefits in all-cause and cardiovascular mortality or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding with greater absolute benefits in VP. The effects of bivalirudin vs UFH on MACE and NACE were consistent in VP and non-VP. Bivalirudin was associated with lower all-cause and cardiovascular mortality in VP but not in non-VP, with borderline interaction testing. Bivalirudin reduced bleeding in both VP and non-VP with a larger absolute benefit in VP.
Conclusions:
In acute coronary syndrome patients undergoing invasive management, the effects of randomized treatments were consistent in VP and non-VP, but absolute risk reduction with radial access and bivalirudin were greater in VP, with a 5- to 10-fold lower number needed to treat for benefits. Trial registry number: NCT01433627.
Keywords:
Acceso radial; Acute coronary syndrome; Acute heart failure; Bivalirudin; Bivalirudina; Cardiac arrest; Insuficiencia cardiaca aguda; Paciente vulnerable; Parada cardiaca; Radial access; Síndrome coronario agudo; Vulnerable patients.
Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Acute Coronary Syndrome* / complications
-
Acute Coronary Syndrome* / drug therapy
-
Anticoagulants / therapeutic use
-
Antithrombins
-
Heparin
-
Hirudins
-
Humans
-
Out-of-Hospital Cardiac Arrest* / drug therapy
-
Peptide Fragments
-
Percutaneous Coronary Intervention*
-
Recombinant Proteins
-
Treatment Outcome
Substances
-
Anticoagulants
-
Antithrombins
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
Heparin
Associated data
-
ClinicalTrials.gov/NCT01433627